Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

Next Previous
Trial Profile

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin degludec (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms onset8
  • Sponsors Novo Nordisk

Most Recent Events

  • 01 Jun 2019 Post hoc analysis of Onset 1 and Onset 8 trial published in the Diabetes Therapy.
  • 05 Oct 2018 Results of post hoc analysis of onset 8 study assessing the impact of dose adjustment methodology (DAM) in relation to the efficacy and safety of mealtime faster aspart in T1D. presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
  • 30 Aug 2018 Primary endpoint has been met. (Change from baseline in HbA1c after 26 weeks of treatment) as per results published in the European Clinical Trials Database Trial Registry

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top